Company intelligence / Profile preview

EpiThany, Inc.

Washington, District of Columbia, United Statesecstigers.com ↗

Ownership: Private
Development stage: Phase 2

Overview

EpiThany has advanced its lead therapeutic vaccine candidate into Phase II clinical trials targeting solid tumors such as breast cancer. The company’s technology enables robust Th1-driven anti-tumor immunity across a spectrum of cancers. No published pivotal or late-stage results were identified; ongoing studies focus on safety and efficacy in early-to-mid clinical development.

Therapeutic areas: Oncology
Modalities: Therapeutic vaccinesDNA vaccinesmRNA vaccinesRecombinant polypeptides
Industry: Biotech

Drug pipeline

1 asset

STEMVAC

Partnerships

Collaborations with University of Washington/Tumor Vaccine Groupindustry partners mentioned generally

Beyond the preview

Go deeper on EpiThany, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiThany, Inc..

Explore the full profile